Education
About Us
Working with TipRanks
Follow Us
Ibio Inc (IBIO)
NASDAQ:IBIO
IBIO Stock Chart & Stats
$2.22
-$0.02(-0.74%)
At close: 4:00 PM EST
$2.22
-$0.02(-0.74%)
Day’s Range― - ―
52-Week Range$0.56 - $6.89
Previous CloseN/A
Volume55.53K
Average Volume (3M)2.35M
Market Cap
$76.69M
Enterprise Value$10.47M
Total Cash (Recent Filing)$28.67M
Total Debt (Recent Filing)$2.45M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
May 18, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding34,543,560
10 Day Avg. Volume1,189,877
30 Day Avg. Volume2,350,228
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.54
Price to Sales (P/S)20.03
P/FCF Ratio-0.52
Enterprise Value/Market Cap0.14
Enterprise Value/Revenue34.92
Enterprise Value/Gross Profit952.24
Enterprise Value/Ebitda-0.71
Forecast
1Y Price Target
$5.00Price Target Upside125.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biological RationaleHuman genetic evidence and supportive data from RNAi competitors indicate activin E inhibition may improve body composition, reduce liver fat, and lower metabolic disease risk, strengthening the scientific case for IBIO-610.
Development Funding And Trial ReadinessNonclinical and manufacturing studies support initiation of a first-in-human trial, while a private placement provides funding to advance core cardiometabolic programs toward clinical testing.
Program DifferentiationIBIO-610 is the only known antibody-based activin E program, offering scarcity value and potential advantages over RNA approaches such as fully scalable manufacturing and potential co-formulation with GLP-1 therapies.
Bears Say
Cash Runway And BurnLimited cash resources combined with a high annualized cash burn create pressure to secure additional financing to sustain development of later-stage programs.
Clinical Outcome UncertaintyLack of disclosed weight-loss outcomes for activin E approaches leaves uncertainty whether target suppression will translate into meaningful clinical benefits, raising program execution risk.
Financing And Dilution RiskA substantial fully diluted share base increases the risk of investor dilution if new capital is raised, which could weigh on the stock.
Ibio News
IBIO FAQ
What was Ibio Inc’s price range in the past 12 months?
Ibio Inc lowest stock price was $0.56 and its highest was $6.89 in the past 12 months.
What is Ibio Inc’s market cap?
Ibio Inc’s market cap is $76.69M.
When is Ibio Inc’s upcoming earnings report date?
Ibio Inc’s upcoming earnings report date is May 18, 2026 which is in 91 days.
How were Ibio Inc’s earnings last quarter?
Ibio Inc released its earnings results on Feb 10, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.14 by $0.05.
Is Ibio Inc overvalued?
According to Wall Street analysts Ibio Inc’s price is currently Undervalued.
Does Ibio Inc pay dividends?
Ibio Inc does not currently pay dividends.
What is Ibio Inc’s EPS estimate?
Ibio Inc’s EPS estimate is -0.06.
How many shares outstanding does Ibio Inc have?
Ibio Inc has 34,543,560 shares outstanding.
What happened to Ibio Inc’s price movement after its last earnings report?
Ibio Inc reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.14. Following the earnings report the stock price went down -2.643%.
Which hedge fund is a major shareholder of Ibio Inc?
Currently, no hedge funds are holding shares in IBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ibio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (125.23% Upside)
$5.00 (125.23% Upside)
Blogger Sentiment
Bullish
IBIO Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-42.66%
12-Months-Change
Fundamentals
Return on Equity
-70.22%
Trailing 12-Months
Asset Growth
196.78%
Trailing 12-Months
Company Description
Ibio Inc
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
IBIO Stock 12 Month Forecast
Average Price Target
$5.00
▲(125.23% Upside)
Technical Analysis
Minerva Neurosciences
―
Pulmatrix
―
Chemomab Therapeutics
―
Aspire Biopharma Holdings
―
FibroBiologics, Inc.
―
Ownership Overview
1.13%
Insiders
1.26% Mutual Funds
9.62% Other Institutional Investors
85.08% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---